Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia
NCT: NCT06982820 · RECRUITING
Brief Summary
The purpose of this research is to learn more about a new treatment for individuals with Major Depressive Disorder (MDD) with heightened symptoms of anhedonia (i.e. loss of pleasure or interest in activities). The treatment is called Prism, and it is a software device intended for a novel form of neurofeedback training to be used in a clinic setting. During this study, the subject will use different techniques to measure brain activities, including magnetic resonance imaging (MRI) and electroencephalography (EEG).
Frequently Asked Questions
What is Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia?
Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia is a clinical trial registered under NCT06982820. Current status: RECRUITING.
What is the status of NCT06982820?
The current status of NCT06982820 (Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia) is: RECRUITING.
When did Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia start?
Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia started on 2025-06-25.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.